Treatment needs and current options for postmenopausal osteoporosis

Luigi Gennari, Stefano Rotatori, Simone Bianciardi, Ranuccio Nuti, Daniela Merlotti

Research output: Contribution to journalReview article

Abstract

Introduction: Osteoporosis is a chronic, skeletal disorder characterized by compromised bone strength and increased risk of fractures, affecting up to 50% of postmenopausal women worldwide. Over the past 2 decades there have been consistent developments in the pharmacotherapy of osteoporosis with the availability of potent inhibitors of bone resorption (bisphosphonates, and denosumab) or stimulators of bone formation (PTH analogs) with substantial improvements over calcitonin or estrogen replacement. Areas covered: In this review we summarize the effects of existing treatment options for postmenopausal osteoporosis along with the unmet clinical needs and we discuss about the potential benefits of new compounds under development. Expert opinion: Despite the recent progresses, there are still limitations and unmeet needs with all the available drugs, mainly concerning treatment adherence, efficacy on the prevention of nonvertebral fractures and the long-term adverse events of antiresorptive regimens. Moreover, PTH analogs are the only available compounds able to stimulate bone formation, but with a restricted anabolic window of no more than 2 years. Of interest, the more recent advances in bone biology identified new targets for the development of drugs with a more potent and selective activity on either osteoclasts or osteoblasts, thus making possible to uncouple bone formation from bone resorption.
Original languageEnglish
Pages (from-to)1141 - 1152
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume17
Issue number8
DOIs
Publication statusPublished - May 23 2016

Fingerprint

Postmenopausal Osteoporosis
Osteogenesis
Bone and Bones
Osteoporosis
Bone Density Conservation Agents
Estrogen Replacement Therapy
Diphosphonates
Expert Testimony
Calcitonin
Osteoclasts
Bone Resorption
Osteoblasts
Pharmaceutical Preparations
Therapeutics
Drug Therapy

Keywords

  • abaloparatide
  • bisphosphonates
  • cathepsin K
  • denosumab
  • odanacatib
  • Osteoporosis
  • romosozumab
  • sclerostin
  • SERMS
  • teriparatide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Gennari, L., Rotatori, S., Bianciardi, S., Nuti, R., & Merlotti, D. (2016). Treatment needs and current options for postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy, 17(8), 1141 - 1152. https://doi.org/10.1080/14656566.2016.1176147

Treatment needs and current options for postmenopausal osteoporosis. / Gennari, Luigi; Rotatori, Stefano; Bianciardi, Simone; Nuti, Ranuccio; Merlotti, Daniela.

In: Expert Opinion on Pharmacotherapy, Vol. 17, No. 8, 23.05.2016, p. 1141 - 1152.

Research output: Contribution to journalReview article

Gennari, L, Rotatori, S, Bianciardi, S, Nuti, R & Merlotti, D 2016, 'Treatment needs and current options for postmenopausal osteoporosis', Expert Opinion on Pharmacotherapy, vol. 17, no. 8, pp. 1141 - 1152. https://doi.org/10.1080/14656566.2016.1176147
Gennari, Luigi ; Rotatori, Stefano ; Bianciardi, Simone ; Nuti, Ranuccio ; Merlotti, Daniela. / Treatment needs and current options for postmenopausal osteoporosis. In: Expert Opinion on Pharmacotherapy. 2016 ; Vol. 17, No. 8. pp. 1141 - 1152.
@article{fbae83fa62d949fea4d7fc3dc21d6ecb,
title = "Treatment needs and current options for postmenopausal osteoporosis",
abstract = "Introduction: Osteoporosis is a chronic, skeletal disorder characterized by compromised bone strength and increased risk of fractures, affecting up to 50{\%} of postmenopausal women worldwide. Over the past 2 decades there have been consistent developments in the pharmacotherapy of osteoporosis with the availability of potent inhibitors of bone resorption (bisphosphonates, and denosumab) or stimulators of bone formation (PTH analogs) with substantial improvements over calcitonin or estrogen replacement. Areas covered: In this review we summarize the effects of existing treatment options for postmenopausal osteoporosis along with the unmet clinical needs and we discuss about the potential benefits of new compounds under development. Expert opinion: Despite the recent progresses, there are still limitations and unmeet needs with all the available drugs, mainly concerning treatment adherence, efficacy on the prevention of nonvertebral fractures and the long-term adverse events of antiresorptive regimens. Moreover, PTH analogs are the only available compounds able to stimulate bone formation, but with a restricted anabolic window of no more than 2 years. Of interest, the more recent advances in bone biology identified new targets for the development of drugs with a more potent and selective activity on either osteoclasts or osteoblasts, thus making possible to uncouple bone formation from bone resorption.",
keywords = "abaloparatide, bisphosphonates, cathepsin K, denosumab, odanacatib, Osteoporosis, romosozumab, sclerostin, SERMS, teriparatide",
author = "Luigi Gennari and Stefano Rotatori and Simone Bianciardi and Ranuccio Nuti and Daniela Merlotti",
year = "2016",
month = "5",
day = "23",
doi = "10.1080/14656566.2016.1176147",
language = "English",
volume = "17",
pages = "1141 -- 1152",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Treatment needs and current options for postmenopausal osteoporosis

AU - Gennari, Luigi

AU - Rotatori, Stefano

AU - Bianciardi, Simone

AU - Nuti, Ranuccio

AU - Merlotti, Daniela

PY - 2016/5/23

Y1 - 2016/5/23

N2 - Introduction: Osteoporosis is a chronic, skeletal disorder characterized by compromised bone strength and increased risk of fractures, affecting up to 50% of postmenopausal women worldwide. Over the past 2 decades there have been consistent developments in the pharmacotherapy of osteoporosis with the availability of potent inhibitors of bone resorption (bisphosphonates, and denosumab) or stimulators of bone formation (PTH analogs) with substantial improvements over calcitonin or estrogen replacement. Areas covered: In this review we summarize the effects of existing treatment options for postmenopausal osteoporosis along with the unmet clinical needs and we discuss about the potential benefits of new compounds under development. Expert opinion: Despite the recent progresses, there are still limitations and unmeet needs with all the available drugs, mainly concerning treatment adherence, efficacy on the prevention of nonvertebral fractures and the long-term adverse events of antiresorptive regimens. Moreover, PTH analogs are the only available compounds able to stimulate bone formation, but with a restricted anabolic window of no more than 2 years. Of interest, the more recent advances in bone biology identified new targets for the development of drugs with a more potent and selective activity on either osteoclasts or osteoblasts, thus making possible to uncouple bone formation from bone resorption.

AB - Introduction: Osteoporosis is a chronic, skeletal disorder characterized by compromised bone strength and increased risk of fractures, affecting up to 50% of postmenopausal women worldwide. Over the past 2 decades there have been consistent developments in the pharmacotherapy of osteoporosis with the availability of potent inhibitors of bone resorption (bisphosphonates, and denosumab) or stimulators of bone formation (PTH analogs) with substantial improvements over calcitonin or estrogen replacement. Areas covered: In this review we summarize the effects of existing treatment options for postmenopausal osteoporosis along with the unmet clinical needs and we discuss about the potential benefits of new compounds under development. Expert opinion: Despite the recent progresses, there are still limitations and unmeet needs with all the available drugs, mainly concerning treatment adherence, efficacy on the prevention of nonvertebral fractures and the long-term adverse events of antiresorptive regimens. Moreover, PTH analogs are the only available compounds able to stimulate bone formation, but with a restricted anabolic window of no more than 2 years. Of interest, the more recent advances in bone biology identified new targets for the development of drugs with a more potent and selective activity on either osteoclasts or osteoblasts, thus making possible to uncouple bone formation from bone resorption.

KW - abaloparatide

KW - bisphosphonates

KW - cathepsin K

KW - denosumab

KW - odanacatib

KW - Osteoporosis

KW - romosozumab

KW - sclerostin

KW - SERMS

KW - teriparatide

UR - http://www.scopus.com/inward/record.url?scp=84965028126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965028126&partnerID=8YFLogxK

U2 - 10.1080/14656566.2016.1176147

DO - 10.1080/14656566.2016.1176147

M3 - Review article

VL - 17

SP - 1141

EP - 1152

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 8

ER -